Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes.
Hello and welcome to Eye on AI. In this week’s edition: The difficulty of labeling AI-generated content; a bunch of new reasoning models are nipping at OpenAI’s heels; Google DeepMind uses AI ...
Johnnie Walker has once again elevated luxury with the South African launch of its limited-edition Blue Label Ice Chalet. Hosted at The Forum in Hyde Park, this exclusive event transformed the venue ...